placeholder
Importance
62
Trust
89
Urgency
30
REGULATORY · PRIMARY SOURCE
Drug Safety Communications
Analysis
FDA dropped the suicide warning from GLP-1 drugs in Jan 2026. That removes a label risk that had worried doctors prescribing Ozempic and Wegovy.
- 1-13-2026: FDA requests removal of suicidal behavior and ideation warning from GLP-1 RA medications
- 6-10-2026: FDA approves labeling changes for OTC weight loss drug alli (Orlistat) to warn of kidney stones and kidney injury
- 1-11-2024: FDA update on ongoing evaluation of suicidal thoughts in patients taking diabetes and obesity medicines
FDA Drug Approvals & Databases10d
Read